Hikal Q1 FY27 Results (NSE: HIKAL)
Signal: Loss narrowed
The read
The operating inflection continued from the Q1FY26 trough: revenue rose 5.9% YoY to ₹402.8 Cr and EBITDA grew 47.4% YoY to ₹38.8 Cr, but the 9.6% margin remains 1,070bps below Q4FY26 and reported EBIT was still negative ₹3.9 Cr; recovery is being led by pharmaceuticals while crop-protection cost pressure and regulatory remediation remain the gating risks.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹402.8 Cr | 5.9% | -22.4% |
| EBIT | ₹-3.9 Cr | 70.7% | N/A |
| Net profit | ₹-7.4 Cr | 67.0% | N/A |
| EPS | ₹-0.6 | 67.0% | N/A |
| EBIT margin | 9.6% |
P&L walk
Consolidated revenue was ₹402.8 Cr, +5.9% YoY but -22.4% QoQ, while EBITDA was ₹38.8 Cr, +47.4% YoY, lifting margin to 9.6%; EBIT remained negative at ₹3.9 Cr and the XBRL reports PAT at ₹0.
Segments
Pharmaceuticals was the clear driver, with revenue of ₹233 Cr, +15.2% YoY and 58% of the group versus 53% a year earlier; Crop-Protection declined 4.5% YoY to ₹170 Cr as CDMO inventory adjustments and higher input costs persisted.
Key positives
- Pharmaceuticals revenue reached ₹233 Cr, +15.2% YoY, with its group share rising to 58% from 53% a year earlier.
- EBITDA increased 47.4% YoY to ₹38.8 Cr and the XBRL EBITDA margin improved to 9.6% from 6.6% in Q1FY26.
- Crop-protection own products delivered volume-led growth, while domestic demand improved.
- The company passed 100+ customer audits at its Bangalore facility and increased the DMF filing trajectory to 5–6 annually versus 2–3 historically.
Key concerns
- Crop-Protection revenue fell 4.5% YoY to ₹170 Cr, with CDMO demand affected by customer inventory adjustments.
- Geopolitical developments caused a significant rise across all input costs including raw materials, creating margin pressure despite EBITDA margin recovery.
- The US FDA remediation plan remains in its penultimate stage and has slowed pharmaceutical sales through additional plant shutdowns.
- EBIT was still negative at ₹3.9 Cr and the XBRL reports consolidated PAT of ₹0 Cr, indicating that the operating recovery has not yet produced consistent bottom-line profitability.
Research and educational content only. Not investment advice.